Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts
Kite was sold on to Gilead Sciences, along with FDA-approved CAR-T therapy Yescarta, one of the first two of the groundbreaking cell therapies to reach the market, just behind
Latest news
-
Gilead strikes deal with NHS England on CAR-T Yescarta
Gilead strikes deal with NHS England on CAR-T Yescarta. NHS England claims adult leukaemia access is first in Europe. ... Not far behind Yescarta in the NICE process in DLBCL is Novartis’Kymriah.
-
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
This leaves the appraisal of Gilead’s Yescarta just a month ahead of its rival, with the second appraisal meeting on it scheduled for 27 September. ... This adds to Gilead’s advantage in clinical trial data, where its Yescarta looks to have
-
Gilead optimistic about Yescarta deal in UK
Of the patients treated with a single infusion of Yescarta, 72% responded to therapy (overall response rate). ... Kymriah earned $16m in the second quarter, while Yescarta has reached $68m, ahead of consensus forecasts.
-
Novartis’ CAR-T Kymriah gets green light in England
Novartis’ CAR-T Kymriah gets green light in England. Speedy decision contrasts with NICE's 'no' to rival Yescarta in larger adult DLBCL population. ... The rapid agreement on Kymriah is in stark contrast to NICE’s speedy rejection in draft guidance
-
It’s a no for Yescarta, says NICE on heels of EU approval
It’ s a no for Yescarta, says NICE on heels of EU approval. ... T Yescarta, rejecting use of the cancer immunotherapy by the NHS in draft guidance.
More from news
Approximately 4 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June ... Kymriah and Yescarta might
-
Bluebird Bio: on the cusp of a gene therapy revolution
drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... rival Yescarta also providing price guides once they gain approval, also likely by the end of this year.
-
Health on instalment
Cancer drugs Kymriah and Yescarta go for $475, 000 and $375, 000 respectively.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Experienced Editor, London, Medical Communications
-
Competitive package
- Account Director – Global Healthcare PR
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Account Manager, Healthcare Advertising
-
Salary TBC
- Director Healthcare PR Communications
-
Salary TBC
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
-
Scientific Team Lead
-
Competitive Salary
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director - Digital
-
Great salary and benefits
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
Associate Medical Director
-
Salary TBC
-
Account Director
-
Negotiable
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
Subscribe to our email news alerts
PMHub
Apex.co.uk Conferences, Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...
Latest intelligence
- Tackling a formidable foe
- Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
- Cancer care – the power of new technologies
- With patient numbers set to soar, how can we make a difference?...
- Redefining communications excellence
- How to be heard in today’s multichannel, multistakeholder, multimedia world...
Quick links
Infographics
